Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Definium Therapeutics, Inc. (DFTX : NSDQ)

• Company Description    Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK. Number of Employees: 106

• Price / Volume Information    Yesterday's Closing Price: $38.09 Daily Weekly Monthly 20 Day Moving Average: 2,029,800 shares Shares Outstanding: 134.37 (millions) Market Capitalization: $5,118.04 (millions) Beta: 2.23 52 Week High: $49.70 52 Week Low: $8.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.64% -15.26% 12 Week 60.24% 56.83% Year To Date 184.47% 152.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE WORLD TRADE CENTER SUITE 8500 - NEW YORK,NY 10007 USA ph: 212-220-6633 fax: - ir@definiumtx.com http://www.definiumtx.com

• General Corporate Information    Officers Robert Barrow - Chief Executive Officer and Director Brandi L. Roberts - Chief Financial Officer Carol Vallone - Director David Gryska - Director Roger Crystal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 24477V105 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 134.37 Most Recent Split Date: 8.00 (0.07:1) Beta: 2.23 Market Capitalization: $5,118.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.57 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -188.00% vs. Previous Quarter: -102.82% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -84.01 03/31/26 - -100.30 12/31/25 - -82.07 ROA 06/30/26 - -63.66 03/31/26 - -69.22 12/31/25 - -58.73 Current Ratio 06/30/26 - 6.95 03/31/26 - 4.69 12/31/25 - 6.29 Quick Ratio 06/30/26 - 6.95 03/31/26 - 4.69 12/31/25 - 6.29 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 6.84 03/31/26 - 2.80 12/31/25 - 3.36 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.04 03/31/26 - 0.15 12/31/25 - 0.12 Debt-to-Capital 06/30/26 - 3.82 03/31/26 - 12.76 12/31/25 - 10.88

Powered by Zacks Investment Research ©